M20-178
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed Refractory Myelofibrosis (TRANSFORM-2)
More Information
ENHANCE
A Randomized, Double-Blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine versus Azacitidine Plus Placebo in Treatment-Naive Patients with Higher Risk Myelodysplastic Syndrome
More Information
INCB 50465-313
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of P13K
δ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
More Information
INCB 39110-213
A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants with Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy
More Information
INCB 50465-304
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
SLSG18-301
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
VIALE-M
Randomized, Open-Label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
More Information